Guildford, United Kingdom

ANGLE is a specialist diagnostics company. Its proprietary Parsortix technology can capture and harvest very rare cells, including CTCs (circulating tumour cells), from a blood sample. The FDA approval for its clinical use to guide precision cancer care will open up further multiple commercial opportunities.

Investment Perspective

ANGLE’s updates reveal dialogue with FDA for Parsortix’s approval for use in mBC (metastatic breast cancer) is continuing and constructive, first submissions for accreditation of UK and US clinical laboratories have been made, but development of the ovarian cancer LDT (Laboratory Developed Test) has been hampered by a delay to data read out from a key study (due to third-party supply issues) to H122. A new study comparing CTC harvest and downstream analysis against biopsies in mBC shows good correlation and indicates Parsortix use could materially benefit clinical diagnoses and treatments. The longer wait for FDA approval and first LDT roll-out prompt us to revisit our forecasts and valuation models. Our new valuation of £506m ($658m), or 215p/share compares to £581m ($755m), 248p/share previously.

Market information

SymbolPrimary exchanges


FY21 results: prepared for commercial success
Lighthouse | 28 Apr 2022
FDA approval awaited, LDT data expected H122
Update | 17 Jan 2022
Poised to disrupt existing tumour assay protocols
Update | 01 Oct 2021

Recent News

FY21 results
28 Apr 2022
Parsortix poster presented at AACR
14 Apr 2022
Identifying drug targets in cancer metastasis
01 Apr 2022
Rapid information on patient response to therapies
29 Mar 2022